Novogen Revenue 2006-2020 | KZIA

Novogen revenue from 2006 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Novogen Annual Revenue
(Millions of US $)
2020 $1
2019 $1
2018 $0
2017 $0
2016 $1
2015 $0
2014 $0
2013 $1
2012 $2
2011 $2
2010 $9
2009 $8
2008 $12
2007 $15
2006 $10
2005 $13
Novogen Quarterly Revenue
(Millions of US $)
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
2008-12-31
2008-06-30
2007-12-31
2007-06-30
2006-12-31
2006-06-30
2005-12-31
2005-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.145B $0.001B
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29